TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04158531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG sensing and stimulation
Description: Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
Study: NCT02313467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of 1.5% Butenyl ALA
Study: NCT03010800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With Yoni.Fit
Description: Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
Study: NCT02211599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% protein
Description: Meal to provide 15%en from protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% protein
Description: Meal to provide 30%en from protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweetened beverage
Description: Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
Study: NCT03010800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without Yoni.Fit
Description: Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
Study: NCT02881515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet
Description: Ten days of low sodium diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet
Description: Ten days of low sodium diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Sodium Diet
Description: Ten days of a medium sodium diet
Study: NCT02313467

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Topical application of sham control
Study: NCT04184063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBMI
Description: NBMI active treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison
Study: NCT04501315

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, cerebrospinal fluid and urine samples
Description: In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, cerebrospinal fluid and urine samples
Description: In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, cerebrospinal fluid and urine samples
Description: In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, cerebrospinal fluid and urine samples
Description: In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
Study: NCT04477252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-core
Description: Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
Study: NCT00679120

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford Uni Knee
Description: Oxford Uni Knee inserted at the time of surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford Uni Knee
Description: Oxford Uni Knee inserted at the time of surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford Uni Knee
Description: Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
Study: NCT05496127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Exercises and Yoga
Description: Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Exercises and Yoga
Description: Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
Study: NCT02234531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVER TEACHER
Description: The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment.

Intervention type: DEVICE
Group type: OTHER
Intervention: NEVER TEACHER
Description: The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
Study: NCT02881515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Sodium Diet
Description: Ten days of a medium sodium diet
Study: NCT02039037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
Study: NCT02881515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet
Description: Ten days of a high sodium diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Diet
Description: Ten days of a high sodium diet
Study: NCT02645474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS block with ropivacaine
Description: Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block with ropivacaine
Description: Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Amidic local anesthetic standardly used for nerve block and infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Amidic local anesthetic standardly used for nerve block and infiltration
Study: NCT02549404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study: NCT04244552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATRC-101
Description: ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATRC-101
Description: ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATRC-101
Description: ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATRC-101
Description: ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Study: NCT02039037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture (device 585)
Description: Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
Study: NCT01250977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00303966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT03491865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL media Plus curriculum
Description: REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
Study: NCT01940042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO2 was removed by means of trandelenburg positions
Study: NCT00937924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meperidine, Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine, Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine, Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Study: NCT02211599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweetened beverage
Description: Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
Study: NCT01003379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619
Description: TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided with exactly the same shape, size and appearance.
Study: NCT03117842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated text and voice messages
Description: Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
Study: NCT01353014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice with genetic information
Description: This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General dietary recommendations
Description: This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
Study: NCT04667442

Intervention type: DIAGNOSTIC_TEST
Intervention: Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)
Description: COVID-19 Rapid Antigen Diagnostic Test
Study: NCT02790502

Intervention type: DEVICE
Group type: OTHER
Intervention: Food Photography Application©
Description: Group testing RFPM as method of recording plate waste
Study: NCT02285816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1MA3
Description: MG1MA3: Boosting component of Oncolytic Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1MA3
Description: MG1MA3: Boosting component of Oncolytic Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdMA3
Description: AdMA3: Priming component of Oncolytic Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdMA3
Description: AdMA3: Priming component of Oncolytic Vaccine
Study: NCT01286870

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Becker 25 Expander/Breast Implant
Description: The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc.

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Becker 50 Expander/Breast Implant
Description: The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc.
Study: NCT01753323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 was supplied as tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 was supplied as tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 was supplied as tablets for oral use.
Study: NCT01657071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14659
Description: YH14659 capsule by oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel & aspirin
Description: clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
Study: NCT02115542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.
Study: NCT03558750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth
Study: NCT03950739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
Study: NCT02978456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent
Description: In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus \~10% of distal reference vessel diameter).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent
Description: In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
Study: NCT01972841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match solifenacin succinate
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match solifenacin succinate
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match solifenacin succinate
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match mirabegron
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match mirabegron
Description: Oral tablet
Study: NCT04244552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surface-bound methoxypolyethylene glycol
Study: NCT03821454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
Study: NCT01972841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match mirabegron
Description: Oral tablet
Study: NCT02844933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral solution
Study: NCT01972841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match mirabegron
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match mirabegron
Description: Oral tablet
Study: NCT03871751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe and Sound Protocol
Description: The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
Study: NCT00684411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Study: NCT00080756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic estradiol
Description: 0.35mg/100ul per day as a nasal spray

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic estradiol
Description: 0.35mg/100ul per day as a nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deslorelin
Description: 1mg/100ul per day as a nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deslorelin
Description: 1mg/100ul per day as a nasal spray
Study: NCT01972841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match mirabegron
Description: Oral tablet
Study: NCT00080756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic testosterone
Description: 0.275mg/100ul per day as a nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic testosterone
Description: 0.275mg/100ul per day as a nasal spray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo risk reduction mastectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: Undergo continued surveillance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies